There is anecdotal evidence suggesting that AKT inhibitors are effective in meningiomas with AKT1 mutations.251 The tumor suppressor activity of NF-2 is modulated partly by eliminating the interactions with FAK signaling, and NF-2 inactivation or q22 deletion with tumor cells has been revealed to respond to FAK inhibition.310 GSK2256098, a FAK inhibitor, is currently found to function in the treatment of NF-2 mutation-associated meningiomas (NCT02523014). The gene discussed is PTK2; the disease is neoplasm.